中枢神经系统：原发性和复发性神经胶质瘤治疗的显著进展。

Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas.

机构信息

Presented by Louis Burt Nabors, MD, Department of Neurology, Division of Neuro-Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):681-4. doi: 10.6004/jnccn.2016.0192.

DOI:10.6004/jnccn.2016.0192

PMID:27226514

Abstract

Over the past 30 years, the incidence of primary brain tumors has been increasing. Primary brain tumors are a heterogeneous group of central nervous system cancers with a wide range of outcomes and therapeutic strategies. As a result, prognostic features and molecular markers play a critical role in selecting treatment options for patients with brain tumors. At the NCCN 21st Annual Conference, Louis Burt Nabors, MD, reviewed the most appropriate adjuvant therapy for 3 types of brain tumors-primary low-grade gliomas, anaplastic oligodendrogliomas, and malignant gliomas-and shared supportive clinical trial data and NCCN recommendations.

摘要

在过去的 30 年中，原发性脑肿瘤的发病率一直在上升。原发性脑肿瘤是一组异质性的中枢神经系统癌症，其预后和治疗策略差异很大。因此，预后特征和分子标志物在为脑肿瘤患者选择治疗方案方面起着至关重要的作用。在 NCCN 第 21 届年会上，Louis Burt Nabors，医学博士，回顾了 3 种脑肿瘤（低级别胶质瘤、间变性少突胶质细胞瘤和恶性胶质瘤）的最佳辅助治疗方法，并分享了支持性临床试验数据和 NCCN 建议。